TITLE

New Therapies in HIV/AIDS Treatment

AUTHOR(S)
Garmany, Justin; Kramer, Richard
PUB. DATE
June 2008
SOURCE
Drug Formulary Review;Jun2008 Supplement, Vol. 24, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the developments in therapies for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). It emphasizes the positive effect of highly reactive antiretro-viral therapy (HAART) on the quality of life, T cell count and survival in HIV patients. The current available therapies include nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), fusion inhibitors and integrase inhibitors.
ACCESSION #
32588594

 

Related Articles

  • Mutations in HIV-1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to Nonnucleoside Reverse-Transcriptase Inhibitors: Effect on Response to Efavirenz-Based Therapy in an Urban Observational Cohort. Tozzi, Valerio; Zaccarelli, Mauro; Narciso, Pasquale; Trotta, Maria Paola; Ceecherini-silberstein, Francesca; De Longis, Patrizio; D'offizi, Giampiero; Forbici, Federica; D'arrigo, Roberta; Boumis, Evangelo; Bellagamba, Rita; Bonfigli, Sandro; Carvelli, Chiarina; Antinori, Andrea; Federico Perno, Carlo // Journal of Infectious Diseases;5/1/2004, Vol. 189 Issue 9, p1688 

    Background. Hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was described in association with reverse-transcriptase (RT) mutations conferring resistance to nucleoside reverse-transcriptase inhibitors (NRTIs). We evaluated the effect of RT mutations associated with...

  • Antiretroviral Drug Resistance and Routine Therapy, Cameroon. Laurent, Christian; Kouanfack, Charles; Vergne, Laurence; Tardy, Michèle; Zekeng, Léopold; Noumsi, Nathalie; Butel, Christelle; Bourgeois, Anke; Mpoudi-Ngolé, Eitel; Koulla-Shiro, Sinata; Peeters, Martine; Delaporte, Eric // Emerging Infectious Diseases;Jun2006, Vol. 12 Issue 6, p1001 

    Among 128 patients routinely receiving highly active antiretroviral therapy in an HIV/AIDS outpatient clinic in Cameroon, 16.4% had drug resistance after a median of 10 months. Of these, 12.5% had resistance to nucleoside reverse transcriptase inhibitors (NRTIs), 10.2% to non- NRTIs, and 2.3% to...

  • Targeting Divalent Metal Ions at the Active Site of the HIV-1 RNase H Domain: NMR Studies on the Interactions of Divalent Metal Ions with RNase H and Its Inhibitors. Jiangli Yan; Haihong Wu; Tom, Tiffany; Brodsky, Oleg; Maegley, Karen // American Journal of Analytical Chemistry;Oct2011, Vol. 2 Issue 6, p639 

    HIV-1 reverse transcriptase (RT) RNase H (HIV-RH) is a key target of anti-AIDS drugs. Metal-chelating compounds are an important class of chemicals in pharmacological drug discovery, especially in relation to HIV-RT and the highly-related HIV-integrase. The correlation between the...

  • The HIV-1 Nucleocapsid Zinc Finger Protein as a Target of Antiretroviral Therapy. Musah, Rabi Ann // Current Topics in Medicinal Chemistry;Nov2004, Vol. 4 Issue 15, p1605 

    Despite advances made in its therapeutic management, human immunodeficiency virus (HIV) infection has remained an intractable problem, and complete eradication of the virus an unrealized goal. Experience in the clinical application of combination therapy using a variety of reverse transcriptase...

  • Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial. Vispo, Eugenia; Barreiro, Pablo; Maida, Ivana; Mena, Alvaro; Blanco, Francisco; Rodríguez-Novoa, Sonia; Morello, Judit; Jimenez-Nacher, Inmaculada; Gonzalez-Lahoz, Juan; Soriano, Vincent // HIV Clinical Trials;Jul/Aug2010, Vol. 11 Issue 4, p197 

    Background: Raltegravir has demonstrated good antiviral activity and safety profile in twice-daily (bid) dosing. However, its long terminal elimination half-life might allow once-daily (qd) administration. Methods: Consecutive HIV-infected individuals at our clinic under protease inhibitor...

  • Viral Dynamic Model of Antiretroviral Therapy Including the Integrase Inhibitor Raltegravir in Patients with HIV-1. Bon, Dimitra; Stephan, Christoph; Keppler, Oliver T.; Herrmann, Eva // Biomath;Oct2012, p1 

    Antiviral combination therapies consisting of reverse transcriptase inhibitors, protease inhibitors and an integrase inhibitor, have been developed to suppress HIV below the limit of detection[3]. We introduce a mathematical model for the effect of different combination treatment regimens on the...

  • Long-Term Responses to Treatment including Ritonavir or Nelfinavir in HIV-1-Infected Children. Nadal, D.; Steiner, F.; Cheseaux, J.-J.; Lazarevitch, C.-A.Wyler; Aebi, C.; Kind, C.; Rudin, C. // Infection;Oct2000, Vol. 28 Issue 5, p287 

    Background: Knowledge concerning the long-term antiretroviral and immunological efficacy of protease inhibitors in children is limited. Patients and Methods: An open-label, prospective, multicenter clinical trial was conducted over a period of 72 weeks in Switzerland. 60 HIV-1 infected children...

  • Beyond Efficacy: The Impact of Combination Antiretroviral Therapy on Quality of Life. Sax, Paul E.; Gathe Jr., Joseph C. // AIDS Patient Care & STDs;Sep2005, Vol. 19 Issue 9, p563 

    Combination antiretroviral therapy (ART) with two nucleoside reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor (PI) significantly improved the prognosis of patients with HIV. Nevertheless, the usefulness of the first PIs was sometimes compromised by poor tolerability, high pill...

  • The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco. Bakhouch, Khadija; Oulad-Lahcen, Ahd; Bensghir, Rajae; Blaghen, Mohamed; Elfilali, Kamal Marhoum; Ezzikouri, Sayeh; Abidi, Omar; Hassar, Mohamed; Wakrim, Lahcen // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p380 

    Background: The widespread use of antiretroviral agents and the growing occurrence of HIV-1 strains resistant to these drugs have given rise to serious concerns regarding the transmission of resistant viruses to newly infected persons, which may reduce the efficacy of a first-line antiretroviral...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics